{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "L",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 L2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper explicitly states that mutations in LRRK2 are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD), and that PD-associated mutants I2020T and G2019S alter kinase activity.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly defined, and the functional assay targets kinase activity, which is directly relevant to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay",
          "extracted_paper_info": "The paper uses in vitro kinase activity assays and binding assays to evaluate ATP affinity and inhibitor resistance, which are relevant to the disease mechanism.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (kinase activity) is applicable to the disease mechanism described in Step 1."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper provides detailed binding and enzymatic assays with controls (wild-type LRRK2) and replicates (triplicate experiments) for I2020T and G2019S.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type) and replicates are present, and the assay is validated for both variants."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "For I2020T, the paper reports 2-fold lower ATP affinity and 10-fold higher resistance to ATP-competitive inhibitors compared to wild-type.",
          "judgment": "Yes",
          "reasoning": "The data is robust and meets the criteria for PS3_supporting (OddsPath > 2.0)."
        }
      ],
      "final_evidence_strength": "PS3_supporting",
      "overall_conclusion": "Both variants I2020T and G2019S have strong functional evidence due to robust data on ATP affinity and inhibitor resistance, leading to PS3 ratings."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "C",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 C2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper confirms that G2019S is a PD-associated mutation with altered kinase activity, consistent with the disease mechanism.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly defined, and the functional assay targets kinase activity, which is directly relevant to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay",
          "extracted_paper_info": "The paper uses binding and enzymatic assays to evaluate ATP affinity and inhibitor resistance, which are relevant to the disease mechanism.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (kinase activity) is applicable to the disease mechanism described in Step 1."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper provides detailed binding and enzymatic assays with controls (wild-type LRRK2) and replicates (triplicate experiments) for G2019S.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type) and replicates are present, and the assay is validated for both variants."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "For G2019S, the paper reports lower ATP affinity and higher sensitivity to inhibitors compared to wild-type, supporting PS3 ratings.",
          "judgment": "Yes",
          "reasoning": "The data is robust and meets the criteria for PS3_supporting (OddsPath > 2.0)."
        }
      ],
      "final_evidence_strength": "PS3_supporting",
      "overall_conclusion": "Both variants I2020T and G2019S have strong functional evidence due to robust data on ATP affinity and inhibitor resistance, leading to PS3 ratings."
    }
  ]
}